Back to Search
Start Over
Considerations in the Preclinical Assessment of the Safety of Antisense Oligonucleotides
- Source :
- Nucleic Acid Therapeutics. 33:1-16
- Publication Year :
- 2023
- Publisher :
- Mary Ann Liebert Inc, 2023.
-
Abstract
- The nucleic acid therapeutics field has made tremendous progress in the past decades. Continuous advances in chemistry and design have led to many successful clinical applications, eliciting even more interest from researchers including both academic groups and drug development companies. Many preclinical studies in the field focus on improving the delivery of antisense oligonucleotide drugs (ONDs) and/or assessing their efficacy in target tissues, often neglecting the evaluation of toxicity, at least in early phases of development. A series of consensus recommendations regarding regulatory considerations and expectations have been generated by the Oligonucleotide Safety Working Group and the Japanese Research Working Group for the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use S6 and Related Issues (WGS6) in several white papers. However, safety aspects should also be kept in sight in earlier phases while screening and designing OND to avoid subsequent failure in the development phase. Experts and members of the network "DARTER," a COST Action funded by the Cooperation in Science and Technology of the EU, have utilized their collective experience working with OND, as well as their insights into OND-mediated toxicities, to generate a series of consensus recommendations to assess OND toxicity in early stages of preclinical research. In the past few years, several publications have described predictive assays, which can be used to assess OND-mediated toxicity
- Subjects :
- Drug Discovery
Genetics
Molecular Medicine
Molecular Biology
Biochemistry
Subjects
Details
- ISSN :
- 21593345 and 21593337
- Volume :
- 33
- Database :
- OpenAIRE
- Journal :
- Nucleic Acid Therapeutics
- Accession number :
- edsair.doi.dedup.....37d2183c36096e6473337b9648afc92d